INSM Stock Recent News

BRIDGEWATER, N.J. , Aug. 21, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that management will present at the following investor conferences: Wells Fargo 2025 Healthcare Conference in Boston, on Friday, September 5, 2025, at 8:00 a.m.

William Blair initiated coverage on Insmed Incorporated INSM, citing that the clinical and commercial execution of its drugs can significantly increase Insmed's valuation.

Josh Brown, CEO of Ritholtz Wealth Management, joins CNBC's "Halftime Report" to detail his latest addition to his 'Best Stocks in the Marlet,' Insmed.

Stifel raised the firm's price target on Insmed to $145 from $121 and keeps a Buy rating on the shares following FDA's recent approval of Brinsupri as the first approved therapy for treatment of non-CF bronchiectasis. The firm believes the inclusion of FEV1 data in the efficacy section of the prescribing information and a launch price of $88,000 per year for both doses are "upside surprises," the analyst tells investors. 12 Jun

Will Lewis, Insmed CEO, joins 'Fast Money' to discuss the company's lung drug being greenlit by the FDA and what it means for for the stock.

The U.S. Food and Drug Administration (FDA) on Tuesday approved Insmed Incorporated's INSM Brinsupri (brensocatib 10 mg and 25 mg tablets). It is an oral, once-daily treatment for non-cystic fibrosis bronchiectasis (NCFB) in adults and children 12 years and older.

The U.S. Food and Drug Administration has approved Insmed's oral drug for a type of lung disease, the company said on Tuesday, making it the first treatment for the chronic condition.

— Approximately 500,000 U.S. Patients Are Diagnosed with Non-Cystic Fibrosis Bronchiectasis (NCFB), a Progressive Disease That Can Lead to Permanent Lung Damage — — BRINSUPRI  10 mg and 25 mg Doses Approved for the Treatment of NCFB — — BRINSUPRI, a First-in-Class DPP1 Inhibitor Targeting Neutrophilic Inflammation,  Is Available by Prescription Through a Comprehensive Specialty Pharmacy Network — — Insmed to Host Investor Conference Call Today at 12:00 PM ET  — BRIDGEWATER, N.J. , Aug. 12, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved first-in-class BRINSUPRI™ (brensocatib 10 mg and 25 mg tablets), an oral, once-daily treatment for non-cystic fibrosis bronchiectasis (NCFB) in adults and children 12 years and older.

Explore Insmed's (INSM) international revenue trends and how these numbers impact Wall Street's forecasts and what's ahead for the stock.

Insmed Incorporated (NASDAQ:INSM ) Q2 2025 Earnings Conference Call August 7, 2025 8:00 AM ET Company Participants Bryan Dunn - Vice President of Investor Relations Martina Flammer - Chief Medical Officer Roger Adsett - Chief Operating Officer Sara M. Bonstein - Chief Financial Officer William H.